Apollo Hospitals has made a strategic move to strengthen its digital healthcare capabilities by acquiring a majority 51% stake in a healthcare startup. This acquisition represents a significant step in the hospital chain's ongoing efforts to enhance its technology-driven services and improve patient care delivery.

Strategic Digital Expansion

The acquisition of the majority stake demonstrates Apollo Hospitals' commitment to expanding its digital footprint in the healthcare sector. By securing controlling interest in the startup, the healthcare giant aims to leverage innovative technologies and solutions to transform patient experiences and streamline healthcare delivery processes.

Enhanced Patient Care Focus

The primary objective of this acquisition is to boost digital services while simultaneously improving patient care standards across Apollo's network. This strategic investment aligns with the growing trend of healthcare digitization and the increasing demand for technology-enabled medical services.

Market Positioning

This acquisition positions Apollo Hospitals to better compete in the rapidly evolving healthcare landscape, where digital solutions are becoming increasingly important for patient engagement, care coordination, and service delivery. The move reflects the company's forward-thinking approach to healthcare innovation and its dedication to maintaining its leadership position in the Indian healthcare market.

Apollo Hospitals Enterprise Limited has received a no-objection letter from the National Stock Exchange (NSE) for its composite scheme of arrangement, marking a significant regulatory milestone in the healthcare giant's corporate restructuring initiative involving demerger and amalgamation.

NSE Approval with Detailed Conditions

The NSE issued its observation letter on December 23, 2025, conveying no objection to the composite scheme under Regulation 37 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This approval enables the company to file the draft scheme with the National Company Law Tribunal (NCLT).

Comprehensive Scheme Structure

The composite arrangement involves multiple entities and complex corporate actions. The scheme encompasses the demerger of identified business undertaking from Apollo Hospitals Enterprise Limited into Apollo Healthtech Limited, along with amalgamation of Apollo Healthco Limited and Keimed Private Limited into the resultant company.

Key Regulatory Requirements

The NSE approval comes with extensive conditions that the company must fulfill. These include mandatory disclosure of all ongoing adjudication and recovery proceedings against the entity and its promoters before NCLT and shareholders. The company must also ensure that proposed equity shares under the scheme are issued in demat form only.

Additionally, Apollo Hospitals must provide comprehensive disclosures to public shareholders, including details of assets, liabilities, net worth, and revenue of companies involved pre and post-scheme, along with the impact on revenue generating capacity.

Implementation Timeline and Next Steps

The scheme remains subject to receipt of requisite statutory and regulatory approvals, shareholder and creditor approvals, and other terms as set out in the arrangement. The company had previously received approval from the Competition Commission of India on September 24, 2025, for the transactions contemplated under the scheme.

Apollo Healthtech Limited must complete listing steps within sixty days of receiving the NCLT order, with trading to commence simultaneously on all stock exchanges where Apollo Hospitals' equity shares are listed.